6 September 2023 - Astellas was so sure that one of its drugs was going to be selected as part of Medicare’s new drug price negotiation program that the company preemptively sued the Biden administration.

But it turns out that its blockbuster drug Xtandi didn’t get picked for the program, after all. So on Wednesday, the company withdrew its lawsuit.

Read Stat News article